Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.